Please login to the form below

Not currently logged in
Email:
Password:

caplacizumab

This page shows the latest caplacizumab news and features for those working in and with pharma, biotech and healthcare.

Sanofi appoints ex-Roche Reed as new R&D head

Sanofi appoints ex-Roche Reed as new R&D head

Sanofi currently has just one drug pending FDA approval - Ablynx’s caplacizumab, a new treatment for blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP), but needs more filings over the next

Latest news

  • Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

    With operating conditions increasingly tough for its core diabetes franchise as well, Novo has been trying to grow its pipeline, but an attempt to buy Ablynx and its lead product caplacizumab

  • Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

    Both deals boost its positions in rare diseases and haematology, with Ablynx’lead product caplacizumab acquired thrombotic thrombocytopenic purpura (aTTP) slotting neatly into Sanofi’s pipeline along with the Bioverativ haemophilia ... Geel.

  • Ablynx knocks-back Novo Nordisk’s second bid Ablynx knocks-back Novo Nordisk’s second bid

    Ablynx has rejected Novo Nordisk’s proposal to acquire the Belgian biopharma and its lead candidate caplacizumab, stating that the deal wouldn’t be in the “best interests of the company”. ... However Ablynx - whose long-term plan is to become a

  • Novo Nordisk makes improved €2.6bn offer for Ablynx Novo Nordisk makes improved €2.6bn offer for Ablynx

    Danish pharmaceutical company Novo Nordisk is hoping to bolster its haematology franchise after stating interest in Ablynx along with its lead asset caplacizumab - a rare bleeding disorder treatment. ... and global commercialisation of caplacizumab for

  • Belgium's Ablynx enters the US market Belgium's Ablynx enters the US market

    One of his priorities will be to lead the commercialisation of Ablynx’s orphan drug caplacizumab. ... We look forward to joining forces to further develop our commercial infrastructure in preparation of the potential launch of caplacizumab.".

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Strategically caplacizumab represented a good fit for Novo Nordisk as it complements the company's portfolio of products focused on haemophilia. ... Acquisition company. 7, 000. Ablynx/Sanofi. Nanobody platform product pipeline; lead product caplacizumab

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics